tremelimumab   Click here for help

GtoPdb Ligand ID: 8462

Synonyms: CP-675 | CP-675,206 | CP-675206 | Imjudo® | ticilimumab | tremelimumab-actl
Approved drug Immunopharmacology Ligand
tremelimumab is an approved drug (FDA (2022), EMA (2023))
Compound class: Antibody
Comment: Tremelimumab is a fully human investigational monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4, CD152). Tremelimumab was designed as an antineoplastic agent. A BLAST sequence alignment matches tremelimumab to patent US 6682736, and identifies antibody clone 11.2.1 [2].
Click here for help
1. CalabrĂ² L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M et al.. (2015)
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
Lancet Respir Med, 3 (4): 301-9. [PMID:25819643]
2. Hanson DC, Neveu MJ, Mueller EE, Hanke JH, Gilman SC, Davis CG, Corvalan JR. (2004)
Human monoclonal antibodies to CTLA-4.
Patent number: US6682736 B1. Assignee: Abgenix, Inc., Pfizer Inc.. Priority date: 22/12/1998. Publication date: 27/01/2004.
3. Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T. (2015)
A phase 2 study of tremelimumab in patients with advanced uveal melanoma.
Melanoma Res, 25 (4): 342-7. [PMID:26050146]
4. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH. (2006)
Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
Cancer, 106 (11): 2437-44. [PMID:16615096]